ARTICLE | Product Development
Growing worldwide, BeiGene set to open N.J. manufacturing site
Global biotech sees Brukinsa and pipeline as growth engines as it relies on ‘CRO-free’ R&D model, protects supply chain
July 10, 2024 10:20 PM UTC
With its clinical pipeline growing and its Btk inhibitor gaining market share, BeiGene is now set to open a major biologics manufacturing site in New Jersey to help ensure uninterrupted supply of its drugs.
Known for its cross-border commercialization of cancer drugs with an early emphasis on China, 14-year-old BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160; Shanghai:688235) now derives the majority of its revenue from outside that market, with nearly half the total coming from the U.S...